Drug profile · INN
concentrate of proteolytic enzymes enriched in bromelain
NEXOBRID
concentrate of proteolytic enzymes enriched in bromelain (NEXOBRID) is a removal of necrotic tissue.
EMA: approved Dermatologicals (D03) D03BA03
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — concentrate of proteolytic enzymes enriched in bromelain
- Class
- Dermatologicals (D03)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
concentrate of proteolytic enzymes enriched in bromelain (NEXOBRID) is a removal of necrotic tissue.
Key facts
INN concentrate of proteolytic enzymes enriched in bromelain
Brand NEXOBRID
Mechanism Removal of necrotic tissue
Therapeutic class Dermatologicals (D03)
ATC code D03BA03
Mechanism of action
Removal of necrotic tissue
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is concentrate of proteolytic enzymes enriched in bromelain?
concentrate of proteolytic enzymes enriched in bromelain (NEXOBRID) is a removal of necrotic tissue.
What is the brand name for concentrate of proteolytic enzymes enriched in bromelain?
NEXOBRID is a marketed brand name for concentrate of proteolytic enzymes enriched in bromelain. Check FDA Drugs@FDA for the current US label holder and prescribing information.